If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 12.66%. Currently, Regeneron Pharmaceut
Dupixent, developed by Regeneron (REGN.US) and Sanofi (SNY.US), has been approved in the EU for the treatment of adult patients with chronic obstructive pulmonary disease.
Dupixent is the first new therapy approved for the treatment of COPD in the European Union for over a decade.
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,183
Morgan Stanley analyst Terence Flynn maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,183.According to TipRanks data, the analyst has a success ra
Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characteriz
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Wednesday the European Commission has approved Dupixent as an additional maintenance treatment for adults with uncontrolled chronic obstructive p
Sanofi and Regeneron Pharmaceuticals Got Approval From European Union
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease
By Adria Calatayud Sanofi and Regeneron Pharmaceuticals got approval from European Union regulators for their Dupixent drug as a therapy for chronic obstructive pulmonary disease, adding a new indica
Express News | Dupixent® (Dupilumab) Approved in the European Union as the First-Ever Targeted Therapy for Patients With Copd
Express News | Sanofi Says Dupixent Granted European Union Approval to Treat Chronic Obstructive Pulmonary Disease (Copd)
Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals(REGN.US) Director Sells US$105.92K in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Director RYAN ARTHUR F sold 100 shares of common stock on Jul 1, 2024 at an average price of $1,059.24 for a total value of $105.92K.Source: Announcement What is s
Regeneron Pharmaceuticals(REGN.US) Officer Sells US$1.19 Million in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Officer McCourt Marion sold 1,137 shares of common stock on Jul 1, 2024 at an average price of $1,047.11 for a total value of $1.19 million.Source: Announcement Wh
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Regeneron Pharmaceuticals's (NYSE:REGN) short percent of float has risen 5.99% since its last report. The company recently reported that it has 1.85 million shares sold short, which is 1.77% of all re
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing
Marion McCourt, Executive Vice President, Commercial, on July 01, 2024, sold 1,137 shares in Regeneron Pharmaceuticals (REGN) for $1,190,564. Following the Form 4 filing with the SEC, McCourt has cont
Regeneron Pharmaceuticals on Pace for Largest Percent Decrease Since November 2023 -- Data Talk
Regeneron Pharmaceuticals, Inc. (REGN) is currently at $1033.16, down $23.86 or 2.26% --Would be lowest close since June 13, 2024, when it closed at $1026.55 --On pace for largest percent decrease s
Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices.
Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices.
Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 1.19 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Regeneron Pharmaceuticals(REGN.US)$ Officer MARION E MCCOURT intends to sell 1,137 shares of its common stock on Jul 1, with a total market value of approximately $1.19